0 Google + 00
Elekta's Clarity soft tissue visualization system cleared for use for cancer patients in China Beijing

2014-11-04

Men with prostate cancer will be the first group of patients in China to benefit from the recent clearance of Elekta's (EKTA-B.ST) Clarity™ soft tissue visualization system by the China Food and Drug Administration (CFDA). As part of Elekta's premiere linear accelerator offering, Versa HD™, Clarity enables clinicians to use non-ionizing ultrasound technology to non-invasively image the prostate and surrounding soft tissues before patients begin treatment.


"As radiation oncology equipment becomes increasingly available to Chinese clinicians, and as demand grows, Elekta is providing world-class solutions, such as Clarity, to meet the specific needs of this market," says Anming Gong, Elekta's Managing Director for China.

The authorization for Clarity use in China follows the CFDA's clearance in September of Elekta's Versa HD™ linear accelerator, enabling Elekta to sell and market the system in China.

According to the International Agency for Research on Cancer, well over three million people are diagnosed with cancer every year in China1. Prostate cancer is the sixth most common cancer for men in China2. 

1. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013.

distributed by